What is he best known for?
The fields of study he is best known for:
- Cancer
- Immune system
- Antibody
His primary areas of investigation include Immunology, Immune system, Immunotherapy, Vaccinia and Carcinoembryonic antigen.
Many of his studies on Immunology apply to Prostvac as well.
His studies deal with areas such as Clinical trial, Combination therapy, Pharmacology and Docetaxel as well as Immune system.
He has researched Immunotherapy in several fields, including Cancer cell, Cytotoxic T cell, Cancer research and Combined Modality Therapy.
His Cancer research research incorporates elements of MHC class I and Chemotherapy.
His Vaccinia research integrates issues from Virology and Vaccination.
His most cited work include:
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy (981 citations)
- Consensus guidelines for the detection of immunogenic cell death (449 citations)
- Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes (395 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Immunology, Immunotherapy, Cancer research, Immune system and Antigen.
James W. Hodge has included themes like Cancer, Carcinoembryonic antigen and Cytotoxic T cell in his Immunology study.
His Immunotherapy research incorporates themes from Cancer cell, Chemotherapy, Pharmacology and Immunogenicity.
His study in Cancer research is interdisciplinary in nature, drawing from both Chimeric antigen receptor, MHC class I, Combination therapy and Antibody-dependent cell-mediated cytotoxicity.
His Immune system study incorporates themes from Vaccinia and Radiation therapy.
His Antigen research is multidisciplinary, incorporating elements of T cell, Viral vector, Vaccination, Vaccine therapy and Tumor antigen.
He most often published in these fields:
- Immunology (55.34%)
- Immunotherapy (44.17%)
- Cancer research (41.75%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (41.75%)
- Immunotherapy (44.17%)
- Immune system (41.26%)
In recent papers he was focusing on the following fields of study:
James W. Hodge spends much of his time researching Cancer research, Immunotherapy, Immune system, Chimeric antigen receptor and Antigen.
His studies in Cancer research integrate themes in fields like CD16, Cancer, Cell therapy and Cancer immunotherapy.
His Immunotherapy research includes elements of T cell, Primary tumor and CD8.
His study on Immune system is mostly dedicated to connecting different topics, such as Combination therapy.
His work in Chimeric antigen receptor covers topics such as PD-L1 which are related to areas like Myeloid, Growth inhibition and Tumor control.
His Antigen research focuses on Immune checkpoint and how it relates to Tumor antigen, Immunodominance, Durvalumab and Ovarian cancer.
Between 2018 and 2021, his most popular works were:
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (106 citations)
- Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study (22 citations)
- Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK (14 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Immune system
- Antibody
James W. Hodge mainly investigates Cancer research, Immune system, Immunotherapy, Immunogenic cell death and Cancer cell.
The study incorporates disciplines such as Head and neck squamous-cell carcinoma and Antibody-dependent cell-mediated cytotoxicity in addition to Cancer research.
His research integrates issues of Interferon and Antibody in his study of Immune system.
Immunotherapy is a subfield of Cancer that James W. Hodge studies.
His Immunogenic cell death research is multidisciplinary, relying on both Acquired immune system, Antigenicity, Pattern recognition receptor, Intracellular and Adjuvanticity.
His Cancer cell study integrates concerns from other disciplines, such as Squamous carcinoma, Neuroscience and Antigen presentation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
